CD274 and non-small cell lung carcinoma: The phase III KEYNOTE-024 study demonstrated that pembrolizumab monotherapy could provide an overall survival (OS) benefit in patients with advanced stage NSCLC, who exhibit a high expression of programmed death-ligand 1 (PD-L1) [4].